SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004587
Filing Date
2024-02-01
Accepted
2024-02-01 12:15:12
Documents
16
Period of Report
2024-02-01
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44665
2 ex3-1.htm EX-3.1 11892
3 ex99-1.htm EX-99.1 16363
  Complete submission text file 0001493152-24-004587.txt   257081

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gtbp-20240201.xsd EX-101.SCH 3024
5 XBRL LABEL FILE gtbp-20240201_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE gtbp-20240201_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3716
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 24585785
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)